ARCHIVES

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

This article is from The Cancer Letter archive.

Vol. 27 No. 17 | April 27, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Statisticians Disputes Bross Claim

April 27, 1979

Relative Survival Now May be Over 50%, DeVita Says

December 3, 1982

FDA News: Rule Limits Drug Pioneers To 30-Month Patent Extension

June 20, 2003

Community Assn. Plan Meeting In DC On Program Problems

November 29, 1974

Panel Suggests Test Of Paid Advertising For ACS: Roundup

August 7, 1992

AGS-003 Increased Survival In Combination with Sunitinib

February 24, 2012